Avalon GloboCare (NASDAQ: ALBT) plans KetoAir breathalyzer launch in UK

Rhea-AI Filing Summary

Avalon GloboCare Corp. filed a current report describing a planned product launch. The company announced that it intends to begin selling its KetoAir™ breathalyzer device in the United Kingdom starting on September 1, 2025. This step represents an international rollout of the KetoAir™ product beyond existing markets. The announcement was made through a press release that is included as an exhibit and is referenced for further details on the planned UK introduction.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001630212 0001630212 2025-08-28 2025-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 28, 2025

AVALON GLOBOCARE CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-38728		47-1685128
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

4400 Route 9 South, Suite 3100, Freehold, NJ 07728

(Address of principal executive offices)

(732) 780-4400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALBT		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 28, 2025, the Company issued a press release announcing that the Company intends to begin selling the KetoAir™ breathalyzer device in the United Kingdom starting September 1, 2025.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release of the Company dated August 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AVALON GLOBOCARE CORP.
Dated: August 28, 2025	By:	/s/ Luisa Ingargiola
	Name:	Luisa Ingargiola
	Title:	Chief Financial Officer

2

FAQ

What did Avalon GloboCare Corp. (ALBT) disclose in this 8-K filing?

Avalon GloboCare Corp. disclosed that it intends to begin selling its KetoAir™ breathalyzer device in the United Kingdom starting on September 1, 2025, as announced in a press release attached to the report.

When will Avalon GloboCare (ALBT) start selling the KetoAir™ device in the UK?

The company stated that sales of the KetoAir™ breathalyzer device in the United Kingdom are expected to begin on September 1, 2025.

What is KetoAir™ in Avalon GloboCare’s (ALBT) disclosure?

KetoAir™ is described as a breathalyzer device that Avalon GloboCare Corp. plans to start selling in the United Kingdom, according to the company’s announcement.

How did Avalon GloboCare (ALBT) communicate the KetoAir™ UK launch?

The company issued a press release on August 28, 2025, announcing its intention to begin selling the KetoAir™ breathalyzer device in the United Kingdom. This press release is attached as Exhibit 99.1.

Is the KetoAir™ UK launch information considered filed financial information?

The company specified that the information under Item 7.01, including the press release, is furnished and not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.

Which exhibit in the Avalon GloboCare (ALBT) 8-K contains details on the KetoAir™ UK launch?

Exhibit 99.1 contains the press release dated August 28, 2025, in which Avalon GloboCare Corp. announces its intention to begin selling the KetoAir™ breathalyzer device in the United Kingdom.